Reported Earnings • Jul 16
Full year 2026 earnings released: EPS: ₹9.05 (vs ₹9.09 in FY 2025) Full year 2026 results: EPS: ₹9.05 (down from ₹9.09 in FY 2025). Revenue: ₹296.1m (up 18% from FY 2025). Net income: ₹27.1m (flat on FY 2025). Profit margin: 9.2% (down from 11% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 28% per year. Duyuru • Jul 06
Crestchem Limited, Annual General Meeting, Aug 06, 2026 Crestchem Limited, Annual General Meeting, Aug 06, 2026. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 90% over the past three years. Duyuru • May 18
Crestchem Limited to Report Q4, 2026 Results on May 26, 2026 Crestchem Limited announced that they will report Q4, 2026 results on May 26, 2026 Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹119, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 18% over the past three years. New Risk • Apr 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.5% average weekly change). Market cap is less than US$10m (₹233.3m market cap, or US$2.49m). Minor Risk Revenue is less than US$5m (₹266m revenue, or US$2.8m). Recent Insider Transactions • Feb 27
Chairman & MD recently bought ₹69k worth of stock On the 23rd of February, Dipak Patel bought around 750 shares on-market at roughly ₹91.45 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹80k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹533k worth in shares. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹2.39 (vs ₹1.74 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.39 (up from ₹1.74 in 3Q 2025). Revenue: ₹73.4m (up 53% from 3Q 2025). Net income: ₹7.17m (up 38% from 3Q 2025). Profit margin: 9.8% (down from 11% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹95.46, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 49% over the past three years. Duyuru • Feb 07
Crestchem Limited to Report Q3, 2026 Results on Feb 13, 2026 Crestchem Limited announced that they will report Q3, 2026 results on Feb 13, 2026 New Risk • Feb 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹269.3m market cap, or US$2.98m). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (8.3% net profit margin). Revenue is less than US$5m (₹243m revenue, or US$2.7m). Reported Earnings • Nov 14
Second quarter 2026 earnings released Second quarter 2026 results: Revenue: ₹73.4m (down 6.0% from 2Q 2025). Net income: ₹5.45m (down 45% from 2Q 2025). Profit margin: 7.4% (down from 13% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 04
Crestchem Limited to Report First Half, 2026 Results on Nov 12, 2025 Crestchem Limited announced that they will report first half, 2026 results on Nov 12, 2025 Duyuru • Aug 06
Crestchem Limited to Report Q1, 2026 Results on Aug 12, 2025 Crestchem Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Reported Earnings • Jul 31
Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024) Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹250.8m (up 18% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 59% per year. Board Change • Jul 31
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Chairman & MD Dipak Patel is the most experienced director on the board, commencing their role in 2008. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jun 24
Crestchem Limited, Annual General Meeting, Aug 21, 2025 Crestchem Limited, Annual General Meeting, Aug 21, 2025, at 12:15 Indian Standard Time. Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹9.09 (vs ₹7.15 in FY 2024) Full year 2025 results: EPS: ₹9.09 (up from ₹7.15 in FY 2024). Revenue: ₹255.2m (up 20% from FY 2024). Net income: ₹27.3m (up 27% from FY 2024). Profit margin: 11% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 60% per year whereas the company’s share price has increased by 58% per year. Duyuru • May 28
Crestchem Limited Recommends Final Dividend for the Financial Year Ended March 31, 2025 Crestchem Limited recommended a final dividend at INR 1.00 (10%) per equity share of face value of INR 10 each for the financial year ended March 31, 2025. The said final dividend, if approved by the members of the Company at the upcoming Annual General Meeting (`AGM') of the Company,
will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company. Duyuru • May 20
Crestchem Limited to Report Q4, 2025 Results on May 28, 2025 Crestchem Limited announced that they will report Q4, 2025 results on May 28, 2025 Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹223, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 433% over the past three years. Recent Insider Transactions • Mar 23
Chairman & MD recently bought ₹80k worth of stock On the 21st of March, Dipak Patel bought around 350 shares on-market at roughly ₹230 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹829k worth in shares. Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹216, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 441% over the past three years. Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹1.74 (vs ₹3.03 in 3Q 2024) Third quarter 2025 results: EPS: ₹1.74 (down from ₹3.03 in 3Q 2024). Revenue: ₹48.0m (down 35% from 3Q 2024). Net income: ₹5.21m (down 43% from 3Q 2024). Profit margin: 11% (down from 12% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹306, the stock trades at a trailing P/E ratio of 29x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 636% over the past three years. Duyuru • Feb 04
Crestchem Limited to Report Q3, 2025 Results on Feb 12, 2025 Crestchem Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Recent Insider Transactions • Jan 02
Chairman & MD recently bought ₹61k worth of stock On the 27th of December, Dipak Patel bought around 250 shares on-market at roughly ₹244 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹176k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹742k worth in shares. Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹294, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 560% over the past three years. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹264, the stock trades at a trailing P/E ratio of 31.6x. Average trailing P/E is 32x in the Chemicals industry in India. Total returns to shareholders of 476% over the past three years. Duyuru • Oct 31
Crestchem Limited to Report Q2, 2025 Results on Nov 12, 2024 Crestchem Limited announced that they will report Q2, 2025 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Oct 25
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹226, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 508% over the past three years. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₹249, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 438% over the past three years. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹190, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 36x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years. Duyuru • Sep 12
Crestchem Limited Announces Resignation of Binaben Parasbhai Patel as Independent Director, Effective September 20, 2024 Crestchem Limited announced resignation of Smt. Binaben Parasbhai Patel as Independent Director, w.e.f. September 20, 2024. Reported Earnings • Aug 07
Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023) Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹212.6m (up 27% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 07
Crestchem Limited to Report Q1, 2025 Results on Aug 12, 2024 Crestchem Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 12, 2024 Board Change • Jul 11
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Nitinkumar Shah was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹144, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 161% over the past three years. Duyuru • Jul 05
Crestchem Limited Announces Director Changes Crestchem Limited at its board meeting held on July 4, 2024 announced appointment of Smt. Priyanka M. Patel as additional director effective from July 4, 2024. Further, the company announced Resignation of Shri Manojkumar B. Patel as Independent Director effective from July 04, 2024, Due to his preoccupations. And Shri Rajesh I Mody ceased to be Independent Director effective from July 4, 2024 as his tenure as Independent director is over. Duyuru • Jul 01
Crestchem Limited, Annual General Meeting, Aug 30, 2024 Crestchem Limited, Annual General Meeting, Aug 30, 2024. Recent Insider Transactions • Jun 25
Chairman & MD recently bought ₹53k worth of stock On the 22nd of June, Dipak Patel bought around 388 shares on-market at roughly ₹136 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹300k. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹811k worth in shares. Recent Insider Transactions • Jun 08
Chairman & MD recently bought ₹300k worth of stock On the 3rd of June, Dipak Patel bought around 2k shares on-market at roughly ₹143 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Dipak has been a buyer over the last 12 months, purchasing a net total of ₹758k worth in shares. Duyuru • May 30
Crestchem Limited Recommends Final Maiden Dividend for the Financial Year Ended March 31, 2024 Crestchem Limited at its Board meeting held on May 28, 2024, recommended a final maiden dividend at INR 0.50 (5%) per equity share of face value of INR 10 each for the financial year ended March 31, 2024. The final dividend, if approved by the members of the company at the upcoming Annual General Meeting of the Company, will be paid/dispatched within stipulated time period of its declaration at the said AGM of the Company. Reported Earnings • May 30
Full year 2024 earnings released: EPS: ₹7.15 (vs ₹2.31 in FY 2023) Full year 2024 results: EPS: ₹7.15 (up from ₹2.31 in FY 2023). Revenue: ₹215.2m (up 29% from FY 2023). Net income: ₹21.5m (up 210% from FY 2023). Profit margin: 10.0% (up from 4.1% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 22
Crestchem Limited to Report Q4, 2024 Results on May 28, 2024 Crestchem Limited announced that they will report Q4, 2024 results on May 28, 2024 Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹105, the stock trades at a trailing P/E ratio of 20.3x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 277% over the past three years. Reported Earnings • Feb 14
Third quarter 2024 earnings released: EPS: ₹3.03 (vs ₹0.72 in 3Q 2023) Third quarter 2024 results: EPS: ₹3.03 (up from ₹0.72 in 3Q 2023). Revenue: ₹74.2m (up 85% from 3Q 2023). Net income: ₹9.09m (up 322% from 3Q 2023). Profit margin: 12% (up from 5.4% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹80.60, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 28% over the past three years. Reported Earnings • Nov 05
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: ₹45.5m (up 17% from 2Q 2023). Net income: ₹3.39m (up 176% from 2Q 2023). Profit margin: 7.5% (up from 3.2% in 2Q 2023). The increase in margin was driven by higher revenue. Duyuru • Oct 28
Crestchem Limited to Report Q2, 2024 Results on Nov 04, 2023 Crestchem Limited announced that they will report Q2, 2024 results on Nov 04, 2023 Recent Insider Transactions • Sep 24
Chairman & MD recently bought ₹111k worth of stock On the 22nd of September, Dipak Patel bought around 2k shares on-market at roughly ₹62.47 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹116k. Despite this recent buy, Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k. Duyuru • Aug 05
Crestchem Limited to Report Q1, 2024 Results on Aug 12, 2023 Crestchem Limited announced that they will report Q1, 2024 results on Aug 12, 2023 Reported Earnings • Jul 30
Full year 2023 earnings released: EPS: ₹2.31 (vs ₹1.89 in FY 2022) Full year 2023 results: EPS: ₹2.31 (up from ₹1.89 in FY 2022). Revenue: ₹168.8m (up 112% from FY 2022). Net income: ₹6.93m (up 22% from FY 2022). Profit margin: 4.1% (down from 7.1% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 07
Crestchem Limited, Annual General Meeting, Aug 24, 2023 Crestchem Limited, Annual General Meeting, Aug 24, 2023, at 12:15 Indian Standard Time. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to ₹88.04, the stock trades at a trailing P/E ratio of 35.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 91% over the past year. Valuation Update With 7 Day Price Move • May 18
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹80.65, the stock trades at a trailing P/E ratio of 32.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 95% over the past year. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 863% over the past three years. Recent Insider Transactions • Mar 23
Chairman & MD recently sold ₹226k worth of stock On the 21st of March, Dipak Patel sold around 2k shares on-market at roughly ₹98.48 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹378k. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹112, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 917% over the past three years. Recent Insider Transactions • Mar 13
Chairman & MD recently sold ₹166k worth of stock On the 10th of March, Dipak Patel sold around 2k shares on-market at roughly ₹91.88 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Dipak has been a net seller over the last 12 months, reducing personal holdings by ₹152k. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹83.83, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 629% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹74.95, the stock trades at a trailing P/E ratio of 29.9x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 552% over the past three years. Duyuru • Jan 31
Crestchem Limited to Report Q3, 2023 Results on Feb 11, 2023 Crestchem Limited announced that they will report Q3, 2023 results on Feb 11, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹0.41 (vs ₹0.15 loss in 2Q 2022) Second quarter 2023 results: EPS: ₹0.41 (up from ₹0.15 loss in 2Q 2022). Revenue: ₹39.2m (up ₹39.1m from 2Q 2022). Net income: ₹1.23m (up ₹1.67m from 2Q 2022). Profit margin: 3.1% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Nov 05
Crestchem Limited to Report Q2, 2023 Results on Nov 12, 2022 Crestchem Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 27% share price gain to ₹81.10, the stock trades at a trailing P/E ratio of 41.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 479% over the past three years. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 18% share price gain to ₹52.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 257% over the past three years. Buying Opportunity • Aug 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be ₹51.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improved over the past week After last week's 17% share price gain to ₹43.45, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 15% over the past year. Buying Opportunity • Aug 10
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 1.9%. The fair value is estimated to be ₹51.50, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 02
Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021) Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹79.5m (up 4.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Duyuru • Jul 29
Crestchem Limited, Annual General Meeting, Aug 25, 2022 Crestchem Limited, Annual General Meeting, Aug 25, 2022, at 12:15 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Accounts of the Company for the period (12 months) ended on 31st March 2022, and the Director's and Auditor's Reports thereon; to consider and, if thought fit, to pass with or without modification, the following Resolution as an Ordinary Resolution; and to consider any other business matters. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improved over the past week After last week's 16% share price gain to ₹46.80, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 234% over the past three years. Reported Earnings • Jun 01
Full year 2022 earnings released: EPS: ₹1.89 (vs ₹1.91 in FY 2021) Full year 2022 results: EPS: ₹1.89 (down from ₹1.91 in FY 2021). Revenue: ₹80.2m (up 5.0% from FY 2021). Net income: ₹5.67m (down 1.2% from FY 2021). Profit margin: 7.1% (down from 7.5% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 21% share price gain to ₹47.00, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 201% over the past three years. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improved over the past week After last week's 19% share price gain to ₹50.00, the stock trades at a trailing P/E ratio of 26.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 251% over the past three years. Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.72 (up from ₹0.18 in 3Q 2021). Revenue: ₹26.9m (up 123% from 3Q 2021). Net income: ₹2.15m (up 293% from 3Q 2021). Profit margin: 8.0% (up from 4.6% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 14
Investor sentiment improved over the past week After last week's 15% share price gain to ₹39.05, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 18x in the Chemicals industry in India. Total loss to shareholders of 17% over the past year. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹38.00, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total loss to shareholders of 42% over the past year. Reported Earnings • Oct 28
Second quarter 2022 earnings released: ₹0.15 loss per share (vs ₹0.68 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹217.0k (down 99% from 2Q 2021). Net loss: ₹446.0k (down 122% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹39.40, the stock trades at a trailing P/E ratio of 18x. Average trailing P/E is 18x in the Chemicals industry in India. Total returns to shareholders of 243% over the past three years. Board Change • Sep 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 09
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 07
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Sep 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Non-Executive Independent Director Nitinkumar Shah was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Aug 24
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹51.00, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 16x in the Chemicals industry in India. Total returns to shareholders of 343% over the past three years. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹47.30, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 294% over the past three years. Reported Earnings • Jun 27
Full year 2021 earnings released: EPS ₹1.91 (vs ₹1.48 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹76.4m (up 23% from FY 2020). Net income: ₹5.74m (up 29% from FY 2020). Profit margin: 7.5% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has only increased by 53% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improved over the past week After last week's 16% share price gain to ₹41.10, the stock trades at a trailing P/E ratio of 25.2x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 242% over the past three years. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 16% share price gain to ₹38.15, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years. Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment improved over the past week After last week's 21% share price gain to ₹30.20, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 140% over the past three years. Is New 90 Day High Low • Mar 16
New 90-day low: ₹26.95 The company is down 43% from a price of ₹46.90 on 16 December 2020. Underperformed the Indian market, which is up 13% over the last 90 days. Lagged the Chemicals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹28.60, the stock is trading at a trailing P/E ratio of 13.7x, down from the previous P/E ratio of 16.7x. This compares to an average P/E of 17x in the Chemicals industry in India. Total returns to shareholders over the past three years are 129%.